A phase I study of cetuximab in combination with gemcitabine and radiation for locally advanced pancreatic cancer

A. Bapsi Chakravarthy, Chiao Jillian Tsai, Nathan O'Brien, Albert Lockhart, Emily Chan, Alexander Parikh, Jordan D. Berlin, Nipun Merchant

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

BACKGROUND: Cetuximab is a monoclonal antibody against the epidermal growth factor receptor (EGFR). The primary goal of this phase I study was to determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of gemcitabine when combined with cetuximab plus radiation in patients with locally advanced pancreatic cancer. PATIENTS AND METHODS: Patients with locally unresectable adenocarcinoma of the pancreas were treated with gemcitabine (200mg/m2/week before dose escalation) plus cetuximab (400 mg/m 2 loading dose, 250 mg/m 2 weekly maintenance dose) concurrent with radiation (50.4 Gy). RESULTS: Nine patients were enrolled in the study. One withdrew due to declining performance status before receiving any therapy. Grade 4 allergic reactions to cetuximab caused the withdrawal of 2 patients. Another patient had elevated liver function test results and a stroke after his loading dose of cetuximab. Grade 3 or 4 toxicity developed in 3 of the remaining 5 patients treated with the level 1 dose. Therefore, no further dose escalations were planned. Grade 3 toxicities included nausea, vomiting, ileus, and pneumonitis. One patient had grade 4 diarrhea. CONCLUSIONS: The combination of cetuximab, gemcitabine, and radiation resulted in significant toxicity. A recommended phase II dose could not be determined.

Original languageEnglish (US)
Pages (from-to)112-118
Number of pages7
JournalGastrointestinal Cancer Research
Volume5
Issue number4
StatePublished - Jul 2012
Externally publishedYes

Fingerprint

gemcitabine
Pancreatic Neoplasms
Radiation
Radiation Dosage
Maximum Tolerated Dose
Ileus
Liver Function Tests
Cetuximab
Epidermal Growth Factor Receptor
Nausea
Vomiting
Pancreas
Diarrhea
Pneumonia
Hypersensitivity
Adenocarcinoma
Stroke
Monoclonal Antibodies

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology

Cite this

A phase I study of cetuximab in combination with gemcitabine and radiation for locally advanced pancreatic cancer. / Bapsi Chakravarthy, A.; Tsai, Chiao Jillian; O'Brien, Nathan; Lockhart, Albert; Chan, Emily; Parikh, Alexander; Berlin, Jordan D.; Merchant, Nipun.

In: Gastrointestinal Cancer Research, Vol. 5, No. 4, 07.2012, p. 112-118.

Research output: Contribution to journalArticle

Bapsi Chakravarthy, A, Tsai, CJ, O'Brien, N, Lockhart, A, Chan, E, Parikh, A, Berlin, JD & Merchant, N 2012, 'A phase I study of cetuximab in combination with gemcitabine and radiation for locally advanced pancreatic cancer', Gastrointestinal Cancer Research, vol. 5, no. 4, pp. 112-118.
Bapsi Chakravarthy, A. ; Tsai, Chiao Jillian ; O'Brien, Nathan ; Lockhart, Albert ; Chan, Emily ; Parikh, Alexander ; Berlin, Jordan D. ; Merchant, Nipun. / A phase I study of cetuximab in combination with gemcitabine and radiation for locally advanced pancreatic cancer. In: Gastrointestinal Cancer Research. 2012 ; Vol. 5, No. 4. pp. 112-118.
@article{fc1535cee9234662b9b48bdca0e16cff,
title = "A phase I study of cetuximab in combination with gemcitabine and radiation for locally advanced pancreatic cancer",
abstract = "BACKGROUND: Cetuximab is a monoclonal antibody against the epidermal growth factor receptor (EGFR). The primary goal of this phase I study was to determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of gemcitabine when combined with cetuximab plus radiation in patients with locally advanced pancreatic cancer. PATIENTS AND METHODS: Patients with locally unresectable adenocarcinoma of the pancreas were treated with gemcitabine (200mg/m2/week before dose escalation) plus cetuximab (400 mg/m 2 loading dose, 250 mg/m 2 weekly maintenance dose) concurrent with radiation (50.4 Gy). RESULTS: Nine patients were enrolled in the study. One withdrew due to declining performance status before receiving any therapy. Grade 4 allergic reactions to cetuximab caused the withdrawal of 2 patients. Another patient had elevated liver function test results and a stroke after his loading dose of cetuximab. Grade 3 or 4 toxicity developed in 3 of the remaining 5 patients treated with the level 1 dose. Therefore, no further dose escalations were planned. Grade 3 toxicities included nausea, vomiting, ileus, and pneumonitis. One patient had grade 4 diarrhea. CONCLUSIONS: The combination of cetuximab, gemcitabine, and radiation resulted in significant toxicity. A recommended phase II dose could not be determined.",
author = "{Bapsi Chakravarthy}, A. and Tsai, {Chiao Jillian} and Nathan O'Brien and Albert Lockhart and Emily Chan and Alexander Parikh and Berlin, {Jordan D.} and Nipun Merchant",
year = "2012",
month = "7",
language = "English (US)",
volume = "5",
pages = "112--118",
journal = "Gastrointestinal Cancer Research",
issn = "1934-7820",
publisher = "International Society of Gastrointestinal Oncology",
number = "4",

}

TY - JOUR

T1 - A phase I study of cetuximab in combination with gemcitabine and radiation for locally advanced pancreatic cancer

AU - Bapsi Chakravarthy, A.

AU - Tsai, Chiao Jillian

AU - O'Brien, Nathan

AU - Lockhart, Albert

AU - Chan, Emily

AU - Parikh, Alexander

AU - Berlin, Jordan D.

AU - Merchant, Nipun

PY - 2012/7

Y1 - 2012/7

N2 - BACKGROUND: Cetuximab is a monoclonal antibody against the epidermal growth factor receptor (EGFR). The primary goal of this phase I study was to determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of gemcitabine when combined with cetuximab plus radiation in patients with locally advanced pancreatic cancer. PATIENTS AND METHODS: Patients with locally unresectable adenocarcinoma of the pancreas were treated with gemcitabine (200mg/m2/week before dose escalation) plus cetuximab (400 mg/m 2 loading dose, 250 mg/m 2 weekly maintenance dose) concurrent with radiation (50.4 Gy). RESULTS: Nine patients were enrolled in the study. One withdrew due to declining performance status before receiving any therapy. Grade 4 allergic reactions to cetuximab caused the withdrawal of 2 patients. Another patient had elevated liver function test results and a stroke after his loading dose of cetuximab. Grade 3 or 4 toxicity developed in 3 of the remaining 5 patients treated with the level 1 dose. Therefore, no further dose escalations were planned. Grade 3 toxicities included nausea, vomiting, ileus, and pneumonitis. One patient had grade 4 diarrhea. CONCLUSIONS: The combination of cetuximab, gemcitabine, and radiation resulted in significant toxicity. A recommended phase II dose could not be determined.

AB - BACKGROUND: Cetuximab is a monoclonal antibody against the epidermal growth factor receptor (EGFR). The primary goal of this phase I study was to determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of gemcitabine when combined with cetuximab plus radiation in patients with locally advanced pancreatic cancer. PATIENTS AND METHODS: Patients with locally unresectable adenocarcinoma of the pancreas were treated with gemcitabine (200mg/m2/week before dose escalation) plus cetuximab (400 mg/m 2 loading dose, 250 mg/m 2 weekly maintenance dose) concurrent with radiation (50.4 Gy). RESULTS: Nine patients were enrolled in the study. One withdrew due to declining performance status before receiving any therapy. Grade 4 allergic reactions to cetuximab caused the withdrawal of 2 patients. Another patient had elevated liver function test results and a stroke after his loading dose of cetuximab. Grade 3 or 4 toxicity developed in 3 of the remaining 5 patients treated with the level 1 dose. Therefore, no further dose escalations were planned. Grade 3 toxicities included nausea, vomiting, ileus, and pneumonitis. One patient had grade 4 diarrhea. CONCLUSIONS: The combination of cetuximab, gemcitabine, and radiation resulted in significant toxicity. A recommended phase II dose could not be determined.

UR - http://www.scopus.com/inward/record.url?scp=84867872707&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867872707&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84867872707

VL - 5

SP - 112

EP - 118

JO - Gastrointestinal Cancer Research

JF - Gastrointestinal Cancer Research

SN - 1934-7820

IS - 4

ER -